Publikationen in Zusammenarbeit mit Forschern von Hospital General Universitario Gregorio Marañón (26)

2021

  1. Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03)

    Therapeutic Advances in Medical Oncology, Vol. 13

2018

  1. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

    BMC Cancer, Vol. 18, Núm. 1

  2. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS

    Clinical and Translational Oncology, Vol. 20, Núm. 10, pp. 1261-1267

2015

  1. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial

    JAMA Oncology, Vol. 1, Núm. 2, pp. 149-157

2013

  1. Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: Mature results of the Spanish Lung Cancer Group 0008 study

    Lung Cancer, Vol. 81, Núm. 1, pp. 84-90

2012

  1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

    The Lancet Oncology, Vol. 13, Núm. 3, pp. 239-246

2008

  1. Prognostic value of ERBB2 amplification and protein expression in small cell lung cancer

    Archivos de Bronconeumologia, Vol. 44, Núm. 3, pp. 122-126

2006

  1. Polymorphisms in DNA repair genes modulate survival in cisplatin/ gemcitabine-treated non-small-cell lung cancer patients

    Annals of Oncology, Vol. 17, Núm. 4, pp. 668-675

  2. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: A Spanish Lung Cancer Group trial

    Annals of Oncology, Vol. 17, Núm. 3, pp. 467-472

2004

  1. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer

    Clinical Lung Cancer, Vol. 5, Núm. 6, pp. 360-365

1998

  1. Variaciones histopatologicas del cancer de pulmon en un Hospital Universitario de Madrid (1968-1995). Aspectos epidemiologicos

    Neoplasia, Vol. 15, Núm. 5, pp. 163-168

1996

  1. METASTASIS EN LA MAMA, CARACTERISTICAS CLINICAS Y RADIOLOGICAS. PRESENTACION DE DOS CASOS. REVISION DE LA LITERATURA

    Neoplasia, Vol. 13, Núm. 2, pp. 63-67

  2. Phase II study of mitonafide in non-small cell lung cancer (NSCLC)

    Investigational New Drugs, Vol. 14, Núm. 4, pp. 415-417

  3. QUIMIOTERAPIA CON CISPLATINO, ETOPOSIDO E IFOSFAMIDA EN EL CARCINOMA MICROCITICO DE PULMON

    Neoplasia, Vol. 13, Núm. 3, pp. 78-82

1994

  1. QUIMIOTERAPIE EN EL CANCER DE ENDOMETRIO AVANZADO Y RECURRENTE

    Neoplasia, Vol. 11, Núm. 2, pp. 60-62

  2. SINDROME DE PARINAUD EN UN PACIENTE DE 27 ANOS POR METASTASIS CEREBRAL UNICA, METACRONICA, DE UN CARCINOMA DE PULMON

    Neoplasia, Vol. 11, Núm. 2, pp. 63-66

  3. TRATAMIENTO DEL MELANOMA MALIGNO DISEMINADO. PAPEL DE LA HORMONOTERAPIA

    Oncologia, Vol. 17, Núm. 4, pp. 17-22

1993

  1. FACTORES PRONOSTICOS DE RESPUESTA A LA HORMONOTERAPIA EN EL CARCINOMA DE PROSTATA

    Oncologia, Vol. 16, Núm. 3, pp. 27-33

  2. METASTASIS OSEAS (I). FISIOPATOLOGIA, CLINICA Y DIAGNOSTICO

    Neoplasia, Vol. 10, Núm. 1, pp. 23-26

  3. PAPEL ACTUAL DE LA QUIMIOTERAPIA EN EL CANCER DE PULMON DE CELULAS NO PEQUENAS (CPCNP)

    Neoplasia, Vol. 10, Núm. 3, pp. 94-99